Clinical Trial: Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587944) titled 'Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity' on May 08.

Brief Summary: Chemoresistance in acute myeloid leukemia (AML) is closely associated with the bone marrow microenvironment. Elevated levels of IL-6, leptin, fumarate, and other factors within the bone marrow microenvironment have been shown to enhance oxidative phosphorylation or antioxidant capacity in AML cells, thereby inducing chemoresistance. To explore their potential as prognostic biomarkers or therapeutic targets, this study plans to enroll 405 newly diagnosed AML patients meeting the criteria of the Chinese Guidelines for the Diagnosis and ...